|Bid||286.44 x 800|
|Ask||286.91 x 900|
|Day's Range||277.95 - 287.28|
|52 Week Range||119.01 - 319.19|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||82.63|
|Earnings Date||Oct 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||315.40|
The U.S. FDA has granted Abiomed 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System™.
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates. Early identification of patients requiring right-heart support is critical because prior studies have shown 37% of AMI cardiogenic shock (AMICS) patients exhibit right heart dysfunction1, which results in an eight times increased risk of mortality2.